DE122007000087I1 - Adjuvanzsysteme und impfstoffe - Google Patents

Adjuvanzsysteme und impfstoffe

Info

Publication number
DE122007000087I1
DE122007000087I1 DE122007000087C DE122007000087C DE122007000087I1 DE 122007000087 I1 DE122007000087 I1 DE 122007000087I1 DE 122007000087 C DE122007000087 C DE 122007000087C DE 122007000087 C DE122007000087 C DE 122007000087C DE 122007000087 I1 DE122007000087 I1 DE 122007000087I1
Authority
DE
Germany
Prior art keywords
adjuvancy
vaccines
systems
adjuvancy systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE122007000087C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269522&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122007000087(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9822709.3A external-priority patent/GB9822709D0/en
Priority claimed from GBGB9822703.6A external-priority patent/GB9822703D0/en
Priority claimed from GBGB9822712.7A external-priority patent/GB9822712D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE122007000087I1 publication Critical patent/DE122007000087I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE122007000087C 1998-10-16 1999-10-08 Adjuvanzsysteme und impfstoffe Pending DE122007000087I1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9822709.3A GB9822709D0 (en) 1998-10-16 1998-10-16 Vaccine
GBGB9822703.6A GB9822703D0 (en) 1998-10-16 1998-10-16 Vaccine
GBGB9822712.7A GB9822712D0 (en) 1998-10-16 1998-10-16 Vaccine
PCT/EP1999/007764 WO2000023105A2 (en) 1998-10-16 1999-10-08 Adjuvant systems and vaccines

Publications (1)

Publication Number Publication Date
DE122007000087I1 true DE122007000087I1 (de) 2008-03-27

Family

ID=27269522

Family Applications (2)

Application Number Title Priority Date Filing Date
DE122007000087C Pending DE122007000087I1 (de) 1998-10-16 1999-10-08 Adjuvanzsysteme und impfstoffe
DE69935606.7T Active DE69935606T9 (de) 1998-10-16 1999-10-08 Adjuvanzsysteme und impfstoffe

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69935606.7T Active DE69935606T9 (de) 1998-10-16 1999-10-08 Adjuvanzsysteme und impfstoffe

Country Status (31)

Country Link
US (3) US7357936B1 (de)
EP (5) EP1588714A2 (de)
JP (3) JP2003519084A (de)
KR (1) KR100629028B1 (de)
CN (3) CN101926993B (de)
AR (1) AR020836A1 (de)
AT (1) ATE357252T1 (de)
AU (1) AU750587B2 (de)
BR (1) BRPI9915545B8 (de)
CA (2) CA2773698C (de)
CO (1) CO5210894A1 (de)
CY (2) CY1106596T1 (de)
CZ (1) CZ301212B6 (de)
DE (2) DE122007000087I1 (de)
DK (1) DK1126876T3 (de)
ES (1) ES2284287T3 (de)
FR (1) FR07C0064I1 (de)
HK (1) HK1038695B (de)
HU (2) HU228473B1 (de)
IL (2) IL142395A0 (de)
LU (1) LU91389I2 (de)
MY (1) MY124689A (de)
NL (1) NL300311I2 (de)
NO (1) NO336250B1 (de)
NZ (1) NZ511113A (de)
PL (1) PL201482B1 (de)
PT (1) PT1126876E (de)
SI (1) SI1126876T1 (de)
TR (1) TR200101055T2 (de)
TW (1) TW586936B (de)
WO (1) WO2000023105A2 (de)

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
ATE357252T1 (de) * 1998-10-16 2007-04-15 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
WO2001000232A2 (en) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0025170D0 (en) * 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
AU2002343321A1 (en) * 2001-01-26 2003-01-21 Walter Reed Army Institute Of Research Isolation and purification of plasmodium falciparum merozoite protein-142
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
WO2003002065A2 (en) 2001-06-29 2003-01-09 Chiron Corporation Hcv e1e2 vaccine compositions
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
EP2572707A3 (de) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Mikropartikel mit adsorbierten polypeptidhaltigen Molekülen
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1532161B1 (de) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vektoren zur expression von hml-2-polypeptiden
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2402026A3 (de) 2002-09-13 2012-04-18 Intercell AG Verfahren zum Isolieren von Hepatitis-C-Virus-Peptiden
ES2608048T3 (es) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
WO2004060396A2 (en) * 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
KR100692203B1 (ko) * 2003-01-23 2007-03-09 제일모직주식회사 도광판, 이의 제조 방법, 이를 이용한 백라이트 어셈블리및 이를 이용한 액정표시장치
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
JP2006521321A (ja) * 2003-03-24 2006-09-21 インターツェル・アクチェンゲゼルシャフト 免疫応答を促進するためのミョウバンおよびＴｈ１免疫応答誘起アジュバントの使用
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
EP2258365B1 (de) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Verwendung von organischen verbindungen zur immunstärkung
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
FR2854803B1 (fr) * 2003-05-16 2005-06-24 Aventis Pasteur Composition vaccinale comprenant du phosphate de fer a titre d'adjuvent vaccinal.
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
EP1648500B1 (de) 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogene zusammensetzungen für streptococcus pyogenes
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2811027A1 (de) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus-Vektoren für RSV- und PIV-Impfstoffe
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
EP1784211A4 (de) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen für grampositive bakterien wie streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EA012212B1 (ru) * 2005-02-16 2009-08-28 Новартис Вэксинес Энд Дайэгностикс, Инк. Адъювантная композиция, содержащая фосфат алюминия и 3d-mpl
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
PT1909830E (pt) * 2005-08-02 2011-11-24 Novartis Vaccines & Diagnostic Redução de interferência entre adjuvantes contendo óleo e antigénios contendo tensioactivos
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
KR20080069232A (ko) * 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
ES2420829T3 (es) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
PT2347775T (pt) 2005-12-13 2020-07-14 The President And Fellows Of Harvard College Estruturas em andaime para transplante celular
AR058707A1 (es) 2005-12-22 2008-02-20 Glaxosmithkline Biolog Sa Vacuna, procedimiento para fabricarla y su uso
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EA015271B1 (ru) 2006-01-27 2011-06-30 Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2004226A1 (de) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Lagerung von grippeimpfstoffen ohne kühlung
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
CN1864749B (zh) * 2006-04-12 2010-10-06 成都夸常医学工业有限公司 一种药物组合物及制备方法
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
BRPI0713904A2 (pt) 2006-06-29 2013-06-25 Novartis Ag polipeptÍdeos a partir de neisseria meningitidis
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2064230A2 (de) 2006-08-16 2009-06-03 Novartis AG Immungene aus uropathogenen escherichia coli
KR20090057015A (ko) 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
PL2486938T3 (pl) 2006-09-26 2018-08-31 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
PL2185191T3 (pl) 2007-06-27 2013-02-28 Novartis Ag Szczepionki przeciwko grypie o małej zawartości dodatków
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2009029686A1 (en) 2007-08-27 2009-03-05 Longhorn Vaccines & Diagnostics Llc Immunogenic compositions and methods
CA2861667C (en) 2007-10-01 2017-06-13 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081274A2 (en) 2007-12-21 2009-07-02 Novartis Ag Mutant forms of streptolysin o
EP3508505A1 (de) * 2007-12-24 2019-07-10 ID Biomedical Corporation of Quebec Rekombinante rsv-antigene
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EP2265640B1 (de) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimere faktor-h-bindende proteine (fhbp), die eine heterologe b-domäne enthalten, und anwendungsverfahren
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
US9415006B2 (en) * 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
AR071910A1 (es) * 2008-05-26 2010-07-21 Cadila Healthcare Ltd Vacuna combinada para el papiloma humano y el sarampion. vector. huesped.
WO2009147980A1 (ja) 2008-06-04 2009-12-10 財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
BRPI0915960A2 (pt) * 2008-07-18 2019-09-24 Id Biomedical Corp antígenos de polipeptídeos do vírus sincicial respiratório qimérico
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
CN102307590A (zh) 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
ES2649020T3 (es) * 2009-02-17 2018-01-09 Glaxosmithkline Biologicals S.A. Vacuna inactivada del virus del dengue con adyuvante libre de aluminio
AU2010220824A1 (en) * 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
EP3263128A3 (de) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Zusammensetzungen zur immunisierung gegen staphylococcus aureus
WO2010131111A1 (en) 2009-05-11 2010-11-18 Novartis Ag Antigen purification process for pertactin antigen
ES2606563T3 (es) 2009-06-05 2017-03-24 Infectious Disease Research Institute Adyuvantes lipídicos de glucopiranosilo sintéticos y composiciones de vacuna que contienen los mismos
EP2442826B1 (de) 2009-06-15 2015-07-08 National University of Singapore Influenzaimpfstoff, zusammensetzung und seine verwendung
ES2566646T3 (es) * 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
US20120087937A1 (en) 2009-06-25 2012-04-12 Brigitte Desiree Alberte Colau Novel compositions
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
MX2012000734A (es) 2009-07-16 2012-01-27 Novartis Ag Inmunogenos destoxificados de escherichia coli.
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
ES2641892T3 (es) * 2009-08-26 2017-11-14 Selecta Biosciences, Inc. Composiciones que inducen la ayuda de las células T
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
MX337070B (es) 2009-12-22 2016-02-11 Celldex Therapeutics Inc Método para preparar un conjugado klh-egfrviii.
JP6010463B2 (ja) 2010-01-27 2016-10-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変された結核抗原
ES2910199T3 (es) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
WO2011130379A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
EA023397B1 (ru) 2010-05-26 2016-05-31 Селекта Байосайенсиз, Инк. Комбинированные вакцины с синтетическими наноносителями
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2942061A3 (de) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP3153578A1 (de) 2010-07-06 2017-04-12 Novartis Ag Immunogene zusammensetzungen aus norovirus und verfahren
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
EP2655389A2 (de) 2010-12-24 2013-10-30 Novartis AG Verbindungen
HUE043879T2 (hu) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa RSV-immunizálási rend
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
JP5798356B2 (ja) * 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
EP2694099B1 (de) 2011-04-08 2019-10-16 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
DK3275892T3 (da) 2011-05-13 2020-04-06 Glaxosmithkline Biologicals Sa Præfusions-rsv-f-antigener
EP2726097A4 (de) * 2011-07-01 2015-03-11 Univ California Herpes-virus-impfstoff und verwendungsverfahren
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
FR2977800B1 (fr) * 2011-07-13 2014-03-14 Sanofi Pasteur Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
EP3329936A1 (de) 2011-08-22 2018-06-06 Nanobio Corporation Impfstoff gegen den herpes-simplex-virus als nanoemulsion
EP2753354A4 (de) 2011-09-09 2015-04-15 Nanobio Corp Untereinheitsimpfstoff in nanoemulsionsform für das respiratorische synzytialvirus
WO2013038185A1 (en) 2011-09-12 2013-03-21 Jonathan Norden Weber Methods and compositions for raising an immune response to hiv
CN104023744A (zh) 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
BR112014023092A8 (pt) 2012-03-18 2017-07-25 Glaxosmithkline Biologicals Sa Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
CA2870309C (en) * 2012-04-16 2024-02-20 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
EP2659907A1 (de) * 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
EP2659906A1 (de) * 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
WO2014005958A1 (en) 2012-07-06 2014-01-09 Novartis Ag Immunogenic compositions and uses thereof
PL2890394T3 (pl) 2012-08-31 2019-12-31 Glaxosmithkline Biologicals Sa Stabilizowane białka do immunizacji przeciw staphylococcus aureus
EP2890395A1 (de) 2012-08-31 2015-07-08 Novartis AG Stabilisierte proteine zur immunisierung gegen staphylococcus aureus
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
JP6266000B2 (ja) 2012-10-03 2018-01-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CN104822388A (zh) * 2012-10-19 2015-08-05 哈尔过敏控股有限公司 用于免疫疗法的组合物
RS56886B1 (sr) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals Sa Antigeni pseudomonasa i kombinacije antigena
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3096785B1 (de) 2014-01-21 2020-09-09 Pfizer Inc Immunogene zusammensetzungen mit konjugierten kapselsaccharid-antigenen und verwendungen davon
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CA2942450A1 (en) 2014-03-26 2015-10-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
EP4074726A3 (de) 2014-07-23 2022-11-23 Children's Hospital & Research Center at Oakland Faktor-h-bindende proteinvarianten und verfahren zur verwendung davon
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US9976136B2 (en) 2015-05-14 2018-05-22 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
CA2986494A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
EP3319988A1 (de) 2015-07-07 2018-05-16 Affiris AG Impfstoffe zur behandlung und prävention von ige-vermittelten krankheiten
CN108367063A (zh) 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
CN115305229A (zh) 2016-07-13 2022-11-08 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
EP3518966A1 (de) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Zusammensetzungen und verfahren zur behandlung von persistenten hpv-infektionen
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
EP3545972A4 (de) 2016-11-25 2020-05-13 Mogam Institute For Biomedical Research Impfstoffe gegen varicella-zoster-virus
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
MX2019008564A (es) 2017-01-20 2019-09-19 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas.
CN107537035A (zh) * 2017-08-30 2018-01-05 北京恩元华生物科技有限公司 复合佐剂及含复合佐剂的狂犬疫苗及其制备方法和应用
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
TW202003023A (zh) 2018-03-12 2020-01-16 美商詹森藥物公司 針對***之疫苗
BR112020024285A2 (pt) 2018-06-12 2021-03-02 Glaxosmithkline Biologicals S.A. polinucleotídeos e polipeptídeos de adenovírus
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3117867A1 (en) 2018-11-06 2020-05-14 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3897846A1 (de) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Verfahren zur induzierung einer immunantwort
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
BR112021017584A2 (pt) 2019-03-05 2021-11-09 Glaxosmithkline Biologicals Sa Regime e composições de imunização contra hepatite b
MA55364A (fr) 2019-03-18 2022-01-26 Glaxosmithkline Biologicals Sa Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers
HUE063875T2 (hu) 2019-03-18 2024-02-28 Janssen Pharmaceuticals Inc Eljárások E. coli O-antigén poliszacharidok biokonjugátumainak elõállítására, ezek készítményei és felhasználásuk módszerei
EP3952906A1 (de) 2019-04-10 2022-02-16 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselförmigen saccharidantigenen, kits damit und verwendungen davon
CN112138155B (zh) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 一种复合佐剂***及制备该佐剂的方法
JP2022550884A (ja) 2019-10-02 2022-12-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー スタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）ペプチドおよび使用方法
EP4051696A1 (de) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia-zusammensetzungen und verfahren dafür
IL294445B2 (en) 2020-01-16 2023-10-01 Janssen Pharmaceuticals Inc FIMH mutant, its preparations and their use
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
JP2023514697A (ja) 2020-02-23 2023-04-07 ファイザー・インク 大腸菌組成物およびその方法
CN111920946B (zh) * 2020-08-07 2021-05-28 合肥诺为尔基因科技服务有限公司 环二核苷酸修饰铝纳米粒疫苗佐剂-传递***及基于其的SARS-CoV-2亚单位疫苗
MX2023003169A (es) 2020-09-17 2023-03-27 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas.
KR20230096033A (ko) 2020-10-27 2023-06-29 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그의 방법
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
AR124604A1 (es) 2021-01-12 2023-04-12 Janssen Pharmaceuticals Inc Mutantes de fimh, composiciones con los mismos y uso de los mismos
JP2024506364A (ja) 2021-02-11 2024-02-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖワクチンの製造
IT202100003470A1 (it) 2021-02-16 2022-08-16 Fond Toscana Life Sciences Vaccines against sars-cov-2
US20220265805A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
CN115120713A (zh) * 2021-03-25 2022-09-30 四川大学 氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途
EP4313135A1 (de) 2021-04-01 2024-02-07 Janssen Pharmaceuticals, Inc. Herstellung von e. coli o18 biokonjugaten
EP4333868A1 (de) 2021-05-04 2024-03-13 King Abdullah University Of Science And Technology Immunogene zusammensetzungen von mutiertem sars-cov-2 n-protein und gen und verfahren zur verwendung davon
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202304503A (zh) 2021-05-28 2023-02-01 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024018061A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Use of bordetella strains for the treatment of chronic obstructive pulmonary disease

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2861538D1 (en) 1977-12-20 1982-02-25 Secr Defence Brit Liquid crystal displays
DE2837342A1 (de) 1978-08-26 1980-03-06 Henkel Kgaa Verfahren zur herstellung von hefeautolysat
DE3380307D1 (en) 1982-12-23 1989-09-07 Procter & Gamble Ethoxylated amine polymers having clay soil removal/anti-redeposition properties useful in detergent compositions
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
EP0278940A3 (de) 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis-B-Virus-Oberflächenantigene und sie enthaltende hybride Antigene
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
EP1088830A3 (de) 1987-06-22 2004-04-07 Medeva Holdings B.V. Partikel von Hepatitis B Oberflächenantigen
ATE105858T1 (de) 1987-07-17 1994-06-15 Rhein Biotech Ges Fuer Biotech Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung.
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
DE3834729A1 (de) * 1988-10-12 1990-04-19 Behringwerke Ag Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
ATE159031T1 (de) 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
CA2067003A1 (en) 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
KR100251505B1 (ko) 1991-11-16 2000-05-01 장 스테판느 말라리아원충으로부터의 cs 및 hbsag 사이의 혼성 단백질(hybrid protein between cs from plasmodium and hbsag)
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
DK0835663T3 (da) 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
KR100278157B1 (ko) * 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
PT647140E (pt) * 1992-06-25 2007-12-27 Univ Georgetown Vacinas de papilomavírus
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
DK0812593T4 (da) * 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
CA2163550A1 (en) * 1993-05-25 1994-12-08 Gerald E. Hancock Adjuvants for vaccines against respiratory syncytial virus
DE4322107A1 (de) 1993-07-02 1995-01-12 Siemens Ag Einrichtung zum Auffangen und Kühlen von Kernschmelze
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CN1152935A (zh) 1994-05-16 1997-06-25 麦克公司 ***状瘤病毒疫苗
EP0772619B2 (de) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatorische oligonukleotide
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
ES2264563T3 (es) 1994-10-07 2007-01-01 Loyola University Of Chicago Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
KR0184779B1 (ko) * 1995-04-13 1999-04-01 성재갑 퀼라야 사포나리아 몰리나로부터 분리정제된 사포닌 변이체, 이의 분리정제 방법 및 이를 함유하는 백신 제형
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
ES2325301T3 (es) * 1995-06-23 2009-09-01 Glaxosmithkline Biologicals S.A. Composicion de vacuna que comprende un antigeno polisacarido conjugado, adsorbido sobre fosfato de aluminio.
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5733011A (en) * 1997-02-06 1998-03-31 Richard A. Young Multiple position tool caddy seat
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ES2273482T3 (es) 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Composiciones de vacunas combinadas.
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
BR9913026A (pt) * 1998-08-14 2001-09-25 Merck & Co Inc Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
ATE357252T1 (de) * 1998-10-16 2007-04-15 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
JP2003506081A (ja) 1999-08-06 2003-02-18 グラクソ ウェルカム，ソシエダッド アノニマ ＮＦ−κＢ活性化に関与するプロテインキナーゼＣ相互作用性タンパク質
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
KR20050086924A (ko) 2002-12-20 2005-08-30 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신
DE602004022427D1 (de) 2003-09-10 2009-09-17 Cell Biosciences Inc S Zusammensetzungen basierend auf T-4 Immunstimulierender-Faktor ("TISF") zur Behandlung von Mangel and roten Blutkörperchen, Granulocyten un Blutplättchen
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52

Also Published As

Publication number Publication date
PL348121A1 (en) 2002-05-06
CN101926993A (zh) 2010-12-29
WO2000023105A2 (en) 2000-04-27
CA2347099A1 (en) 2000-04-27
CZ301212B6 (cs) 2009-12-09
PL201482B1 (pl) 2009-04-30
ES2284287T3 (es) 2007-11-01
EP2266604A3 (de) 2011-05-11
US7357936B1 (en) 2008-04-15
HK1038695B (zh) 2007-09-14
IL142395A (en) 2006-08-01
US20080226672A1 (en) 2008-09-18
JP2003519084A (ja) 2003-06-17
CN100406060C (zh) 2008-07-30
BR9915545B1 (pt) 2013-08-06
BRPI9915545B8 (pt) 2021-05-25
HUP0203091A3 (en) 2008-04-28
DK1126876T3 (da) 2007-07-02
KR100629028B1 (ko) 2006-09-26
CY1106596T1 (el) 2010-07-28
HUS1300050I1 (hu) 2019-06-28
DE69935606D1 (de) 2007-05-03
EP1666060A1 (de) 2006-06-07
CA2347099C (en) 2014-08-05
CY2007032I2 (el) 2009-11-04
TR200101055T2 (tr) 2001-09-21
NZ511113A (en) 2002-09-27
US9623114B2 (en) 2017-04-18
SI1126876T1 (sl) 2007-08-31
PT1126876E (pt) 2007-04-30
JP5563189B2 (ja) 2014-07-30
EP2266604A2 (de) 2010-12-29
FR07C0064I1 (fr) 2008-02-01
JP2007262097A (ja) 2007-10-11
NL300311I2 (nl) 2008-04-01
EP1126876A2 (de) 2001-08-29
HK1038695A1 (en) 2002-03-28
CN101926993B (zh) 2013-12-04
CO5210894A1 (es) 2002-10-30
ATE357252T1 (de) 2007-04-15
CZ20011341A3 (cs) 2001-09-12
IL142395A0 (en) 2002-03-10
US20140105992A1 (en) 2014-04-17
KR20010075638A (ko) 2001-08-09
AR020836A1 (es) 2002-05-29
AU1151800A (en) 2000-05-08
CY2007032I1 (el) 2009-11-04
CA2773698C (en) 2015-05-19
CN100558401C (zh) 2009-11-11
US8628784B2 (en) 2014-01-14
JP5667107B2 (ja) 2015-02-12
EP1588714A2 (de) 2005-10-26
EP1797896A1 (de) 2007-06-20
MY124689A (en) 2006-06-30
HU228473B1 (en) 2013-03-28
NO336250B1 (no) 2015-06-29
DE69935606T9 (de) 2021-03-11
CN1572324A (zh) 2005-02-02
NO20011801L (no) 2001-05-30
HUP0203091A1 (hu) 2002-12-28
LU91389I9 (de) 2019-01-02
CA2773698A1 (en) 2000-04-27
JP2012121916A (ja) 2012-06-28
WO2000023105A3 (en) 2000-08-03
AU750587B2 (en) 2002-07-25
BR9915545A (pt) 2001-08-14
EP1126876B1 (de) 2007-03-21
LU91389I2 (fr) 2008-02-14
DE69935606T2 (de) 2007-11-29
NL300311I1 (nl) 2008-02-01
CN1330553A (zh) 2002-01-09
TW586936B (en) 2004-05-11
NO20011801D0 (no) 2001-04-09

Similar Documents

Publication Publication Date Title
DE69935606D1 (de) Adjuvanzsysteme und impfstoffe
BR9711853A (pt) Vacinas
DE69832657D1 (de) Empfangseinrichtungen und Empfangsverfahren
NO20003302D0 (no) Vaksine
DE69835254D1 (de) Empfangseinrichtungen und Empfangsverfahren
DE69823583D1 (de) Kassette und Kassetenliefersystem
DE69840474D1 (de) Temperaturunempfindlicher siliziumoszillator und daraus erzeugte präzesionsspannungsreferenz
ID23575A (id) Pirazolopirimidina-pirazolopirimidina dan pirazolotriazina-pirazolotriazina
DE69938489D1 (de) Bilderzeugungsgerät und System
ID26599A (id) Turunan triazola dan imidazola
DE959898T1 (de) Laktoferrin varianten und verwendungen davon
DE69804320T2 (de) Kraftabgängige detektoren und systemen
DE59914173D1 (de) Zündanlage und zündsteuerverfahren
DE29716012U1 (de) Kissen
DE69842206D1 (de) Echounterdrücker und echounterdrückungsverfahren
DE69800085T2 (de) Absorbierendes kissen
FI991567A (fi) Ilmastointimenetelmä ja ilmastointijärjestelmä
DE29711429U1 (de) Getränkezubereitung und daraus herstellbares Getränk
ATE231696T1 (de) Kopfkissen
KR970056768U (ko) 베개
DE59812220D1 (de) Halte- und trageband
FI3379U1 (fi) Muotoiltu pään tyyny
DE29716297U1 (de) Verschlußkappe und Verschlußkappensystem
FI3215U1 (fi) Tyyny
DE29719538U1 (de) Kissen